AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,400 | -45.0% | 299 | -37.1% | 0.00% | – |
| Q2 2023 | $13,452 | +95.9% | 475 | +58.9% | 0.00% | – |
| Q1 2023 | $6,868 | -19.5% | 299 | -1.6% | 0.00% | – |
| Q4 2022 | $8,536 | -39.0% | 304 | -39.7% | 0.00% | – |
| Q3 2022 | $14,000 | +7.7% | 504 | -15.6% | 0.00% | – |
| Q2 2022 | $13,000 | -31.6% | 597 | -7.0% | 0.00% | – |
| Q1 2022 | $19,000 | – | 642 | +1465.9% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 41 | -16.3% | 0.00% | – |
| Q3 2021 | $3,000 | 0.0% | 49 | 0.0% | 0.00% | – |
| Q2 2021 | $3,000 | -66.7% | 49 | -69.6% | 0.00% | – |
| Q1 2021 | $9,000 | +28.6% | 161 | +5.2% | 0.00% | – |
| Q4 2020 | $7,000 | -88.1% | 153 | -90.8% | 0.00% | – |
| Q3 2020 | $59,000 | -34.4% | 1,662 | -0.6% | 0.00% | – |
| Q2 2020 | $90,000 | +1700.0% | 1,672 | +1186.2% | 0.00% | – |
| Q1 2020 | $5,000 | -44.4% | 130 | -28.6% | 0.00% | – |
| Q4 2019 | $9,000 | -10.0% | 182 | -36.6% | 0.00% | – |
| Q3 2019 | $10,000 | -86.5% | 287 | -80.6% | 0.00% | – |
| Q2 2019 | $74,000 | -30.8% | 1,481 | -6.0% | 0.00% | – |
| Q1 2019 | $107,000 | +148.8% | 1,575 | +66.1% | 0.00% | – |
| Q4 2018 | $43,000 | -36.8% | 948 | +5.6% | 0.00% | – |
| Q3 2018 | $68,000 | +61.9% | 898 | +82.5% | 0.00% | – |
| Q2 2018 | $42,000 | +5.0% | 492 | 0.0% | 0.00% | – |
| Q1 2018 | $40,000 | +700.0% | 492 | +397.0% | 0.00% | – |
| Q4 2017 | $5,000 | +150.0% | 99 | +120.0% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 45 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | -80.0% | 45 | -75.8% | 0.00% | – |
| Q1 2017 | $10,000 | +66.7% | 186 | +20.0% | 0.00% | – |
| Q4 2016 | $6,000 | – | 155 | +3775.0% | 0.00% | – |
| Q3 2016 | $0 | -100.0% | 4 | -98.1% | 0.00% | – |
| Q2 2016 | $8,000 | -11.1% | 210 | +150.0% | 0.00% | – |
| Q2 2015 | $9,000 | -84.7% | 84 | -86.4% | 0.00% | – |
| Q1 2015 | $59,000 | -49.6% | 617 | -41.2% | 0.00% | – |
| Q4 2014 | $117,000 | +875.0% | 1,049 | +424.5% | 0.00% | – |
| Q3 2014 | $12,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |